Association of treatment-achieved HbA1c with incidence of coronary artery disease and severe eye disease in diabetes patients

Diabetes Metab. 2020 Sep;46(4):331-334. doi: 10.1016/j.diabet.2018.08.009. Epub 2018 Sep 10.

Abstract

Aim: To examine the association between treatment-achieved HbA1c values and incidence of both coronary artery disease (CAD) and severe eye disease with different diabetes treatments.

Methods: Associations of treatment-achieved HbA1c were investigated in various treatment groups [diet only; insulin; sulphonylurea (SU) alone; SU with glinides; and antihyperglycaemic agents other than glinides, SU or insulin] taken from a nationwide claims database of 14,633 Japanese diabetes patients. Cox's regression analysis examined risks over a 5.1-year follow-up.

Results: A significant linear trend was associated with HbA1c levels and CAD events in the diet-only group, and CAD risks were significantly higher in insulin and SU groups with HbA1c ≤ 7.0% and > 8.0% than in the diet-only group with HbA1c ≤ 7.0%. In contrast to CAD, a linear association was observed regardless of treatment modality between achieved HbA1c levels and risk of severe diabetic eye disease, but with no significant difference in eye disease risk between groups with HbA1c ≤ 7.0% and 7.1-8.0% in those treated with either SU alone, SU with glinides, or insulin.

Conclusion: These findings suggest that the relationship between treatment-achieved HbA1c and incidence of both CAD and severe diabetic eye disease differed according to treatment, based on a large-scale real-life database. More research is now needed to confirm these findings and to further investigate the underlying mechanisms.

Keywords: Antidiabetic drug; Cardiovascular disease; Cohort study; Diabetic retinopathy; Macrovascular disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Coronary Artery Disease / epidemiology*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / therapy*
  • Diabetic Retinopathy / epidemiology*
  • Diabetic Retinopathy / therapy
  • Diet, Diabetic*
  • Female
  • Glycated Hemoglobin / metabolism*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Incidence
  • Insulin / therapeutic use
  • Intravitreal Injections
  • Light Coagulation
  • Macular Edema / epidemiology*
  • Macular Edema / physiopathology
  • Macular Edema / therapy
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Severity of Illness Index
  • Sulfonylurea Compounds / therapeutic use
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Sulfonylurea Compounds
  • hemoglobin A1c protein, human